AbbVie Inc

4 lis 2026, 23:02 UTC

AbbVie Inc. is trading lower in after-market hours, having retraced from earlier gains and reaching a session low compared to Wednesday's close.

3 lis 2026, 23:02 UTC

AbbVie Inc. is trading lower in after-market hours, having retraced from an earlier gain to a current loss, near the lower end of today's range.

2 lis 2026, 23:06 UTC

AbbVie Inc. gains after director Jennifer L. Davis resigns to become CEO at Align Technology; UBS raises price target to $295 while maintaining Neutral rating.

30 paź 2026, 20:03 UTC

AbbVie reports Q3 sales of $17.404 billion, exceeding estimates, and raises full-year revenue guidance to $67.8 billion, while announcing a 5.2% dividend increase.

29 paź 2026, 23:02 UTC

AbbVie Inc. announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology.

28 paź 2026, 23:02 UTC

AbbVie Inc. is trading modestly higher in after-market hours, supported by positive results from Eli Lilly's trial and Amgen's upcoming financial webcast.

27 paź 2026, 20:07 UTC

AbbVie submits a Biologics License Application for etentamig, showing a 74% response rate in Phase 3 CERVINO trial for relapsed multiple myeloma.

26 paź 2026, 19:16 UTC

AbbVie is set to announce Q3 FY2026 earnings on October 30, with an expected EPS of $3.78 and revenue of $17.4 billion.

23 paź 2026, 23:06 UTC

AbbVie receives FDA approval for a subcutaneous induction regimen of SKYRIZI® for adults with moderately to severely active Crohn's disease.

22 paź 2026, 23:01 UTC

AbbVie announces positive topline results from the Phase 3 INTREPID study evaluating lutikizumab for moderate to severe hidradenitis suppurativa.

21 paź 2026, 23:41 UTC

AbbVie Inc shares are trading modestly lower in after-market hours.

20 paź 2026, 20:08 UTC

AbbVie Inc. received Health Canada approval for SKYRIZI to treat children with moderate to severe plaque psoriasis, expanding pediatric treatment options.

19 paź 2026, 20:07 UTC

AbbVie announces positive Phase 2a study results for ABBV-466 in Crohn's disease, with remission rates of 30.2% at Week 12 and 40.5% at Week 24.

16 paź 2026, 23:51 UTC

AbbVie Inc is trading modestly higher in after-market hours, reaching its highest cumulative return of the day and positioned above its 20-day moving average.

15 paź 2026, 23:01 UTC

AbbVie expands its Board of Directors by appointing Dr. John M. Carethers, increasing the board size to 13 members and confirming his independent status.

14 paź 2026, 23:01 UTC

AbbVie Inc shares advanced modestly during after-market hours on Wednesday, continuing a pattern of higher daily closes since the previous session.

13 paź 2026, 23:56 UTC

AbbVie Inc saw a modest uptick in after-market trading, gaining ground since Tuesday's close, supported by a generally positive backdrop for the biotechnology sector.

12 paź 2026, 23:06 UTC

AbbVie Inc shares advanced in after-market trading, marking the ninth consecutive session of higher closes and settling above its 20-day moving average.

9 paź 2026, 23:00 UTC

AbbVie Inc. is experiencing a notable decline in after-hours trading, reaching its lowest point since Friday's close, reversing a trend of higher closes.

8 paź 2026, 23:05 UTC

AbbVie Inc shares are slightly lower in after-market trading, dipping just below Thursday's close after reaching an early peak.

7 paź 2026, 23:05 UTC

AbbVie Inc received FDA Breakthrough Therapy Designations for telisotuzumab adizutecan, with the stock modestly higher in after-market trading amid strong investor interest.

6 paź 2026, 23:15 UTC

AbbVie Inc's shares are trading modestly lower in after-market hours, continuing a recent trend of fluctuations within a narrow range.

5 paź 2026, 23:00 UTC

AbbVie Inc. updated its Q3 adjusted diluted EPS guidance to $3.73-$3.77, while revising 2026 full-year guidance down to $13.76-$13.96; shares were roughly flat in after-market trading.

2 paź 2026, 23:05 UTC

AbbVie Inc has seen a slight increase in after-market trading, continuing its advance since Friday's close and fluctuating near the upper end of its one-month trading range.

1 paź 2026, 23:15 UTC

AbbVie Inc is experiencing routine after-market trading, advancing slightly since Thursday's close, despite retracing to near the low end of today's range.

30 wrz 2026, 23:00 UTC

AbbVie shares are trading modestly higher in after-market hours following the announcement of a late-breaker presentation at the 2026 European Academy of Dermatology Congress.

29 wrz 2026, 23:45 UTC

AbbVie Inc is seeing a slight increase in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

28 wrz 2026, 23:30 UTC

AbbVie Inc's stock is trading higher in after-market hours following FDA approval of JUVMO™ tablets, the first selective D1/D5 receptor agonist for Parkinson's disease.

25 wrz 2026, 23:51 UTC

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

24 wrz 2026, 20:07 UTC

AbbVie Inc. shares fell slightly despite receiving Health Canada approval for EPKINLY in combination with lenalidomide and rituximab for treating follicular lymphoma.